Contemporary OB/GYN week in review: nipocalimab, exercise in pregnancy, and more
Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.
Contemporary OB/GYN week in review: nipocalimab, exercise in pregnancy, and more
Thank you for visiting the Contemporary OB/GYN® website. Take a look at some of our top stories from last week (Monday, March 25 - Friday, March 29 2024), and click each link to read and watch anything you may have missed.
1.) FDA grants FTD to nipocalimab for treating FNAIT
The FDA's Fast Track Designation for nipocalimab marks a significant step in addressing fetal neonatal alloimmune thrombocytopenia risk in pregnant patients, potentially revolutionizing treatment for this severe condition with unmet medical needs.
Click here for the full article.
2.) Sweating it out: Exercise in pregnancy
Explore the detriments of activity restriction, ACOG recommendations, and the benefits and safety precautions for exercising during pregnancy.
Click here for the full article.
3.) CDC estimates of maternal mortality found overestimated
Cande Ananth, PhD, MPH, discusses a study exposing discrepancies in CDC maternal mortality data, highlighting errors in tracking methods and persistent racial disparities in maternal mortality rates
Click here for the full article.
4.) PCOS status linked to menopause age onset
A recent regression model analysis unveils a 5% prolonged period to menopause in women with polycystic ovary syndrome, prompting further investigation into the condition's impact on reproductive health and the need for diverse longitudinal studies.
Click here for the full article.
5.) Enhancing tubal sterilization decision-making: MyDecision aid study
Discover how a web-based decision aid significantly enhances the quality of tubal sterilization decision-making, offering crucial insights for marginalized populations, as revealed in a recent study.
Recap on reproductive rights with David Hackney, MD, MS
December 20th 2022In this episode of Pap Talk, we spoke with David Hackney, MD, MS, maternal-fetal medicine physician at Case Western Reserve University and chair of ACOG's Ohio chapter for a full recap of where restrictions on reproductive rights have been and where they're going.
Listen
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
S4E3: Myfembree for moderate-to-severe endometriosis pain: Potential for adolescents
March 2nd 2022In this episode of Pap Talk, Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.
Listen
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
